KATHERINE CHIN: Open Payments
NPI 1063863785 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,574 in 88 payments from 23 companies in 2025. Trend: 2023 $526 · 2024 $805 · 2025 $2,574
Food & beverage: $2,459Education: $115
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $333 |
| Janssen Biotech, Inc. | 6 | $307 |
| Madrigal Pharmaceuticals | 9 | $282 |
| Ardelyx, Inc. | 16 | $235 |
| Abbott Laboratories | 2 | $211 |
| Janssen Scientific Affairs, LLC | 2 | $188 |
| Gilead Sciences, Inc. | 4 | $185 |
| ABBVIE INC. | 7 | $133 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $116 |
| GENZYME CORPORATION | 1 | $107 |
Products named: TREMFYA, REZDIFFRA, IBSRELA, DRAGONFLY OPSTAR, EOHILIA, ENTYVIO, DUPIXENT, Livdelzi.
Industry payments across CA — which companies pay providers there.
